Table 1.
Characteristics of peripheral ganglia identified on 18F-DCFPyL PET in patients with prostate cancer (n = 76) and renal cell carcinoma (n = 22)
| Peripheral ganglia | No. of positive patients | No. of positive patients with bilateral involvement | No. involved ganglia |
|---|---|---|---|
| Prostate cancer | |||
| Cervical | 51/76 (67.1%) | 30/51 (58.8%) | 102 R, 86 L |
| C3 | 16/76 | 11/16 | 14 R, 13 L |
| C4 | 22/76 | 10/22 | 18 R, 14 L |
| C5 | 20/76 | 11/20 | 19 R, 12 L |
| C6 | 29/76 | 14/29 | 23 R, 20 L |
| C7 | 20/76 | 11/20 | 14 R, 17 L |
| C8 | 19/76 | 5/19 | 14 R, 10 L |
| Stellate | 50/76 (65.8%) | 20/50 (40.0%) | 41 R, 29 L |
| Celiac | 45/76 (59.2%) | 30/45 (66.7%) | 39 R, 36 L |
| Lumbar | 55/76 (72.4%) | 44/55 (80.0%) | 111 R, 103 L |
| L2 | 13/76 | 8/13 | 10 R, 11 L |
| L3 | 38/76 | 29/38 | 34 R, 33 L |
| L4 | 46/76 | 30/46 | 40 R, 36 L |
| L5 | 28/76 | 22/28 | 27 R, 23 L |
| Sacral | 5/76 (6.6%) | 2/5 (40.0%) | 4 R, 3 L |
| Renal cell carcinoma | |||
| Cervical | 19/22 (86.4%) | 15/19 (78.9%) | 44 R, 48 L |
| C3 | 12/22 | 9/12 | 10 R, 11 L |
| C4 | 5/22 | 2/5 | 2 R, 5 L |
| C5 | 10/22 | 5/10 | 7 R, 8 L |
| C6 | 9/22 | 4/9 | 6 R, 7 L |
| C7 | 12/22 | 9/12 | 10 R, 11 L |
| C8 | 10/22 | 5/10 | 9 R, 6 L |
| Stellate | 10/22 (45.4%) | 7/10 (70.0%) | 8 R, 9 L |
| Celiac | 12/22 (54.5%) | 1/12 (8.3%) | 5 R, 8 L |
| Lumbar | 20/22 (90.9%) | 17/20 (85.0%) | 43 R, 44 L |
| L2 | 7/22 | 4/7 | 6 R, 5 L |
| L3 | 15/22 | 12/15 | 13 R, 14 L |
| L4 | 17/22 | 11/17 | 13 R, 15 L |
| L5 | 13/22 | 8/13 | 11 R, 10 L |
| Sacral | 3/22 (13.6%) | 1/3 (33.3%) | 1 R, 3 L |
R right, L left